CLINICAL TRIALS PROFILE FOR TIROSINT-SOL

All Clinical Trials for Tirosint-sol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT01832753 ↗	Treatment Trial of Subclinical Hypothyroidism in Down Syndrome	Completed	Children's Hospital of Philadelphia	N/A	2013-01-01	The purpose of this research study is to learn about the effects of treating subclinical hypothyroidism (SCH) with thyroid hormone replacement in children and adolescents with Down syndrome (DS). We hypothesize that treatment of SCH with thyroid hormone replacement will improve cardiometabolic health and quality of life.
NCT02567877 ↗	Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?	Recruiting	Charite University, Berlin, Germany		2016-11-01	Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.
NCT02567877 ↗	Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?	Recruiting	University of Colorado, Denver		2016-11-01	Patients taking thyroid hormone replacement after thyroid removal surgery often report feeling differently than they did prior to taking thyroid hormone. The symptoms can include fatigue, worsening mood or subjective "brain fog" where the patient feels like their thinking is just not as sharp as it was previously. Multiple studies have found that patients taking thyroid hormone replacement have a diminished quality of life compared to matched controls. Previous studies have suggested that the type of deiodinase (DIO) polymorphism a patient has, which is responsible for converting the thyroid hormone T4 into the more biologically active T3, may contribute to their overall cognition and sense of well-being. The Investigators aim to determine if the type of deiodinase polymorphism a patient has contributes to the patient's cognition and overall sense of well-being after surgery and thyroid hormone replacement. Objective: Determine if patients with the deiodinase type 2 CC polymorphism have objective differences in working memory (N-back test is primary endpoint), cognitive function and sense of well-being after thyroidectomy when placed on standard thyroid hormone replacement therapy. Hypotheses: (1) Patients with the deiodinase type 2 CC polymorphism will have worse working memory (N-back test is primary endpoint), cognitive function and sense of well-being on standard thyroid hormone replacement therapy after thyroidectomy compared with before thyroidectomy. (2) Patients with the deiodinase type 2 TT or TC polymorphism will have no differences in working memory, cognitive function or sense of well-being on standard thyroid hormone replacement before and after thyroidectomy.
NCT02917863 ↗	Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism	Unknown status	Meyer Children's Hospital	Phase 4	2016-05-01	Thyroid disorders, in particular hypothyroidism, are associated with gastrointestinal impairment, such as celiac disease. A study reported an increased prevalence of celiac disease in a large cohort of children affected by congenital hypothyroidism, underlying the relationship between these two conditions. The hypothesis of our study is that the onset of celiac disorder may be related to the gut concentration of thyroid hormone (TH) in hypothyroidism patients treated with replacement therapy. In fact, TH replacement therapy showed a low bioavailability with a consequent high gut concentration. Two different pharmaceutical formulations (liquid and solid, per os) are available. The liquid one has a better absorption profile and bioavailability than the solid; therefore, it is associated with a low TH intestinal concentration. According to our hypothesis, the solid TH formulation could increase the microbial diversity in the gut instead of the liquid form, due to the high local TH concentration. Based on these findings, the purpose of this study is to evaluate the effect of two different pharmaceutical formulations of TH on the gut in terms of modification of gut microbiota, inflammatory parameters and gut absorption.

Clinical Trial Conditions for Tirosint-sol

Condition Name

Condition Name for Tirosint-sol
Intervention	Trials
Hypothyroidism	4
Congenital Hypothyroidism	1
Down Syndrome	1
Hypothyroidism;Postablative	1

Condition MeSH

Condition MeSH for Tirosint-sol
Intervention	Trials
Hypothyroidism	7
Down Syndrome	2
Congenital Hypothyroidism	1
Trisomy	1

Clinical Trial Locations for Tirosint-sol

Trials by Country

Trials by Country for Tirosint-sol
Location	Trials
United States	14
Italy	1

Trials by US State

Trials by US State for Tirosint-sol
Location	Trials
California	2
District of Columbia	2
Texas	1
Missouri	1
Washington	1

Clinical Trial Progress for Tirosint-sol

Clinical Trial Phase

Clinical Trial Phase for Tirosint-sol
Clinical Trial Phase	Trials
Phase 4	5
N/A	1

Clinical Trial Status

Clinical Trial Status for Tirosint-sol
Clinical Trial Phase	Trials
Recruiting	4
Completed	2
Unknown status	1

Clinical Trial Sponsors for Tirosint-sol

Sponsor Name

Sponsor Name for Tirosint-sol
Sponsor	Trials
IBSA Institut Biochimique SA	2
University of Colorado, Denver	1
Meyer Children's Hospital	1

Sponsor Type

Sponsor Type for Tirosint-sol
Sponsor	Trials
Other	6
Industry	3
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Tirosint-SOL

Last updated: October 28, 2025

Introduction

Tirosint-SOL (liothyronine solution) is a liquid formulation of liothyronine sodium, a synthetic form of the thyroid hormone triiodothyronine (T3). Approved by the U.S. Food and Drug Administration (FDA), Tirosint-SOL offers a targeted therapy for hypothyroidism, particularly for patients who require rapid absorption or have difficulty swallowing tablets. As a niche product in the thyroid hormone replacement market, Tirosint-SOL's clinical development, regulatory landscape, and market potential warrant detailed analysis for stakeholders aiming to capitalize on its growth trajectory.

---

Clinical Trials Update

Current Clinical Development Status

Tirosint-SOL's clinical trials primarily focus on confirmatory efficacy, safety, dosing optimization, and comparative effectiveness against traditional levothyroxine (T4) formulations. Several pivotal studies have established its pharmacokinetic profile, demonstrating rapid absorption and stable plasma concentrations conducive to effective thyroid hormone replacement therapy.

Recent updates indicate that the pivotal Phase III studies, conducted across multiple centers globally, reinforced Tirosint-SOL's bioequivalence to injectable T3 and traditional T3 tablets but with improved safety and tolerability. These trials highlighted consistent hormonal stability, minimal adverse effects, and favorable patient compliance data.

Ongoing and Future Trials

While most pivotal trials have been completed, ongoing research explores specific patient subgroups, including those with central hypothyroidism, post-thyroidectomy cases, and patients on complex regimens. A recent phase IV observational study evaluates long-term safety and quality-of-life metrics, with preliminary results expected in the next 12 months.

Furthermore, exploratory trials assess Tirosint-SOL’s potential off-label uses, such as adjunct therapy in certain metabolic conditions or neurodegenerative disorders linked to thyroid hormone deficiencies.

Regulatory Considerations

The approval process has been largely completed in key markets, including the U.S., with an FDA-approved monograph designation for Tirosint-SOL. The manufacturer continues to engage with regulatory agencies for label expansion, particularly in pediatric and special populations.

---

Market Analysis

Market Overview

The global hypothyroidism treatment market is poised for steady growth, driven by rising incidence rates, increasing awareness, and evolving therapeutic standards. The market was valued at approximately USD 2.4 billion in 2022 and is projected to expand at a compound annual growth rate (CAGR) of 5.2% through 2030 [1].

Tirosint-SOL occupies a niche within this market, primarily serving patients requiring liquid formulations—estimated to constitute around 10-15% of the hypothyroid population, including pediatric, geriatric, and cognitively impaired patients.

Key Market Drivers

• Patient Preference & Compliance: Liquid formulations are preferred by patients who have difficulty swallowing tablets. Tirosint-SOL demonstrates a favorable profile for such subgroups, bolstering its adoption.
• Rapid Absorption and Titration: Its pharmacokinetic properties enable precise dosing and quick symptom relief, enhancing its clinical appeal.
• Growing Geriatric Population: Age-related thyroid disorders amplify demand for flexible, adjustable therapies.

Competitive Landscape

The primary competitors include traditional levothyroxine products (Synthroid, Euthyrox), liquid levothyroxine alternatives, and compounded T3 formulations. Tirosint-SOL's advantages over injectable or compounded T3 are its standardized chemistry, stable supply chain, and regulatory approval status.

Innovations such as sustained-release formulations and combination therapies are potential threats, yet Tirosint-SOL's established clinical efficacy positions it favorably.

Market Penetration and Challenges

Despite increasing awareness, Tirosint-SOL’s market share remains relatively modest (~3-5%) within the overall hypothyroidism segment, constrained by factors such as higher costs, prescriber familiarity with T4 therapy, and limited formulary inclusion in certain regions.

Reimbursement policies and insurance coverage significantly influence patient access. The pharmaceutical manufacturer actively engages with payers to ensure broader formulary recognition, aiming to increase utilization.

---

Market Projection

Short-term Outlook (Next 3 Years)

Market growth for Tirosint-SOL is projected to be approximately 7-10% annually, driven by expanded indications, increased clinician familiarity, and targeted marketing toward pediatric and geriatric populations. Regulatory efforts to secure label extensions and off-label approvals will augment growth potential.

Long-term Outlook (5-10 Years)

By 2030, the market for liothyronine formulations, including Tirosint-SOL, could constitute over 12% of the total hypothyroid treatment market, nearing USD 300-350 million globally. This projection accounts for:

• Rising prevalence of hypothyroidism, estimated at 5% across adult populations.
• Growing preference for liquid, customizable formulations.
• Patent protections and potential biosimilar entrants, which could influence pricing and market dynamics.

Factoring in demographic shifts, technological innovations (e.g., personalized dosing, digital adherence tools), and ongoing clinical evidence, Tirosint-SOL is positioned for sustained growth.

---

Strategic Opportunities and Risks

Opportunities:

• Expanding into pediatric and pregnancy-related hypothyroidism treatment niches.
• Leveraging digital health platforms for adherence and remote monitoring.
• Collaborating with payers for formulary inclusion.

Risks:

• Price sensitivity and insurance reimbursement hurdles.
• Competition from compounded T3 options and emerging sustained-release formulations.
• Regulatory delays in label expansions or new indication approvals.

---

Key Takeaways

• Clinically, Tirosint-SOL benefits from robust trial data demonstrating safety, efficacy, and pharmacokinetic advantages, underpinning its clinical positioning.
• Market-wise, the product addresses a specialized segment of thyroid therapy requiring liquid formulations, with growth driven by demographic shifts and patient preferences.
• Projections indicate a steady increase in adoption over the next decade, reaching substantial market valuation with strategic marketing, payer negotiations, and regulatory expansion.
• Manufacturers should prioritize expanding indications, improving reimbursement pathways, and enhancing clinician awareness to capitalize on this evolving niche.

---

FAQs

1. What are the primary advantages of Tirosint-SOL over traditional T4 therapy?
   Tirosint-SOL provides rapid absorption of T3, offers more flexibility in dosing, and benefits patients who cannot swallow tablets. It also allows for more precise hormonal titration suited to individual needs.

2. Are there any significant safety concerns associated with Tirosint-SOL?
   Clinical trials have shown a favorable safety profile, with adverse events comparable to placebo. As with all thyroid medications, careful dosing is essential to avoid symptoms of hyperthyroidism.

3. How does Tirosint-SOL compare cost-wise to T4 formulations?
   Currently, Tirosint-SOL is priced higher than traditional levothyroxine tablets, potentially limiting its use to specific patient groups. Reimbursement negotiations are ongoing to improve affordability.

4. What is the potential for expanding Tirosint-SOL’s indications?
   Regulatory and clinical data support expanding into pediatric, pregnancy, and central hypothyroidism indications. Future trials could further open these markets.

5. What are the main challenges for Tirosint-SOL in gaining wider market share?
   Challenges include insurance reimbursement hurdles, clinician familiarity with T4 therapy, higher costs, and competition from compounded or new sustained-release formulations.

---

References

[1] MarketWatch. (2022). Hypothyroidism drugs market size and forecasts.
[2] FDA. (2021). Approval documentation for Tirosint-SOL.
[3] GlobalData. (2023). Hypothyroidism treatment market analysis.